Gilvocarcin V, isolated from a Streptomyces culture showed activity against experimental tumors such as sarcoma 180, Ehrlich carcinoma, Meth I fibrosarcoma, MH134 hepatoma and lymphocytic leukemia P388. In particular, 40% of treated mice survived for 60 days, after intraperitoneal administration of gilvocarcin V to mice bearing Ehrlich ascites carcinoma. But it was marginally active against B16 melanoma and did not produce prolongation of lifespan of mice bearing Lewis lung carcinoma.
Gilvocarcin, a group of antibiotics with a novel carbon skeleton1~3) was isolated from the culture broth of Streptomyces gilvotanareus. This antibiotic is strongly active against Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis, but is weakly active against Gram-negative bacteria, such as Escherichia coli and Klebsiella pneumoniae. In the previous report1), the preliminary results of antitumor activity of gilvocarcin against P388 leukemia and sarcoma 180 were described.
This paper describes the antitumor activity against various murine tumors and the effect against the number of peripheral white blood cells. The activity of gilvocarcins V and M was compared in the antitumor activity and the cell growth in tissue culture.
Materials and Methods

Animals
Male mice of ddY, BDF1hybrid strain (BALB/c, female x DBA/2, male) weighing 18~22 g, male mice of CDF1 hybrid strain (C57BL/6, female x DBA/2, male) weighing 20~22 g, male mice of C3H/ He/J weighing 18~22 g and male C57BL/6 weighing 20~22 g were obtained from Shizuoka Agricultural Co-operative Association for Laboratory Animals (Hamamatsu).
Tumor Sarcoma 180 ascites type obtained from National Cancer Center (Tokyo) has been maintained by intraperitoneal passage in ddY mice. For antitumor test against solid type of sarcoma 180, 5 x 106 cells were inoculated subcutaneously at the axillary region of ddY mice. P388 cells (1 x106) donated by the Cancer Chemotherapy Center were inoculated intraperitoneally into CDF1 mice. Ehrlich carcinoma cells (5-106), were transplanted intraperitoneally into ddY mice. Lewis lung carcinoma from Cancer Chemotherapy Center (Tokyo) was inoculated by trocar into C57BL/6 mice for passage and into BDF1 mice for antitumor test. BDF1mice were inoculated with 0.2 ml of 10% homogenate of B16 melanoma tumor. MH134 hepatoma was inoculated into C3H/He mice with 5 x 106 cells intraperitoneally. Ascites tumor of fibrosarcoma originally induced in BALB/c mice with 3-methylcholanthrene (Meth 1)4) has been passaged in the same strain4). For the experiment of antitumor activity, 1 x 106 cells were inoculated intraperitoneally into CDF1 mice.
Gilvocarcins were prepared according to the method of NAKANO et al1). Mitomycin C (Kyowa Hakko Kogyo) and adriamycin (Kyowa Hakko Kogyo) were used as reference antitumor agents.
With the ascites tumors, antitumor activity was evaluated by comparing the mean survival time of the treated animal (T) with that of the control tumor bearing animals (C) i.e., percentage increase in lifespan (ILS); (T/C-1) x 100 (%). Each of the experiments was terminated on the 60th day after inoculation. For the solid tumor, the antitumor activity was evaluated in terms of the inhibitory ratio of tumor growth, comparing the mean size in the treated animals (T) with that in the control (C); i.e. T/C. Tumor sizes were measured periodically with calipers. Tumor volume was calculated by the formula represented in the NCI Protocols for screening5) : Volume (mm3)=1/2 ab2, where a and b represent the larger and smaller diameter, respectively.
LD50 was calculated from the number of survivors at 14 days after a single intravenous or intraperitoneal administration into ddY mice.
Peripheral white blood cells of mice bearing solid sarcoma were counted with Micro Cell Counter (Toa Medical Electronics) 4 or 7 days after tumor transplantation.
For the effect on the growth of KB cells, 1 x 104 cells were incubated in 1 nil of Eagle's minimum essential medium (Nissui) supplemented with 10% calf serum. After 24 hours, drugs were added and cell numbers were counted after 72 hours incubation. The dose of 50% inhibition of cell growth (IC50) was determined.
Results
Acute Toxicity of Gilvocarcin V The LD50 of gilvocarcin V by a single intraperitoneal and intravenous dose were higher than 1,000 mg/kg and 375 mg/kg respectively. For gilvocarcin M, the LD50 was 450 mg/kg by a single intravenous administration.
Effect on Sarcoma 180 Table 1 (Table 2) . Gilvocarcin V was also more effective than mitomycin C and adriamycin when therapy was delayed until day 4 after tumor transplantation (Table 3) . was 115 % at a dose of 5.6 mg/kg, almost equal to optimal dose. Gilvocarcin V was also shown more effective than mitomycin C, since 4 mice out of 5 treated mice survived for 60 days (Table 4) .
Effect on MH134
Mice bearing ascites MH134 were given a single injection of gilvocarcin V on the day after tumor inoculation. Gilvocarcin V produced fairly good ILS value; a dose 200 mg/kg showed the maximum percentage of increase of lifespan with higher than 221 % and 60 % of treated mice survived more than 60 days. Mitomycin C was optimal at a dose of 4 mg/kg with 173 % ILS, but no mice survived until 60 days (Table 5 ).
Effects on P388
Gilvocarcin V was intraperitoneally injected day 1 or day 1~5 beginning 24 hours after inoculation of 108 tumor cells. As shown in Table 6 , a single injection of 400 mg/kg gave 57% ILS, and the administration of 200 mg/kg/day for 5 consecutive days produced 69% ILS. The compound was less effective against P388 than mitomycin C which gave 114 and 96 % ILS by single and 5 successive administrations respectively. Gilvocarcin M did not show antitumor activity against P388 at doses examined (Exp. 3 in Table 6 ).
Effect on B16 Melanoma
Gilvocarcin V was effective against ascites tumor of B16 melanoma and produced 40 % ILS at a dose of 400 mg/kg on day 1. But the activity of gilvocarcin V was lower than that of mitomycin C which gave 72% of the maximum increase in lifespan by a single intraperitoneal injection (Table 7) . Table 8 . At a dose of 400 mg/kg/day, gilvocarcin V caused marked inhibition of tumor growth on day 12 to day 18. However the prolongation of the lifespan of the treated mice was not produced in this administration schedule. Mitomycin C which showed a suppressive effect of tumor growth at a dose of 6 mg/kg, also did not produce the prolongation of the lifespan of treated mice.
Effect on KB Cells IC50 was 0.012 mcg/ml for gilvocarcin V, 0.52 mcg/ml for gilvocarcin M and 0.64 mcg/ml for gilvocarcin A which was prepared from gilvocarcin V as described in the previous reportlt. 
Discussion
It is apparent from the present results that gilvocarcin V has a broad spectrum of activity against a number of experimental neoplasms in mice. In particular, gilvocarcin V is markedly effective against the ascites tumor. Among the various tumor lines examined, ascitic Ehrlich carcinoma and MH134 responded especially well to gilvocarcin V. For Ehrlich ascites carcinoma, it produced 200% ILS and gave four 60-day survivors per 5 mice. But mitomycin C gave 173 % ILS and no 60-day survivors. For MH134, the optimal dose of gilvocarcin V made 50% of treated mice survive more than 60 days, but no mice survived after administration of mitomycin C. Solid tumor was less susceptible to gilvocarcin V than ascites tumor and significant activity was obtained only by successive administration schedule.
As the LD50 of gilvocarcin V was higher than 1,000 mg/kg by a single intraperitoneal administration and optimal dose was not determined in several tumor systems, the correct therapeutic ratio (Optimal dose/Dose of 30%ILS) could not be calculated. The safety margin of gilvocarcin V might be very high in an ascites tumor system, because, in the i.p.-i.p. system of P388, a typical example of the i.p.-i.p. system, the dose range of gilvocarcin V which gave ILS over 30% was shown from 12.5 mg/kg to 400 mg/ kg.
Myelosuppressive activity of gilvocarcin V was not observed in ddY mice bearing sarcoma 180. On the contrary, a slight increase in the number of peripheral white blood cells was observed after 5 successive injections of gilvocarcin V. The result might suggest an irritating property of gilvocarcin V in mice.
As gilvocarcin V was virtually insoluble in water, the therapeutic efficacy of the p.o. administration was a subject of discussion. But it was not effective against sarcoma 180 by oral administration.
Gilvocarcin M, 8-methylisomer of gilvocarcin V, and gilvocarcin A, 8-aldehydeisomer of gilvocarcin V were not active against P388 (i.p.-i.p.) (unpublished observation). Gilvocarcins M and A were 50 times less effective than gilvocarcin V on the growth of KB cells. These results may indicate the importance of the 8-vinyl group for the antitumor activity, but the difference in solubility of gilvocarcins M, A and V may also contribute to their activity.
